Aging and Longevity: Short and sweet

A truncated version of the only insulin receptor in C. elegans has been discovered.
  1. Coleen T Murphy  Is a corresponding author
  1. Department of Molecular Biology, Princeton University, United States
  2. LSI Genomics, Princeton University, United States

It would be hard to overstate the importance of a receptor called DAF-2 to our understanding of aging and longevity. Almost 30 years ago it was discovered that loss of the daf-2 gene doubles lifespan in the worm C. elegans (Kenyon et al., 1993), and a few years later it was reported that DAF-2 is the only insulin/IGF-1-like receptor in C. elegans (Kimura et al., 1997). These findings led to an explosion of research into aging and longevity, revealing an intricate insulin signaling pathway that coordinates the sensing of nutrient levels with the regulation of age-related decline. In particular, it was found that reduced insulin signaling extends lifespan and increases stress resistance in flies and mice (Clancy et al., 2001; Holzenberger et al., 2003). Moreover, mutations in some of the genes associated with this pathway were found in centenarians (Suh et al., 2008). And in worms it became clear that, in addition to longevity and age-related declines, DAF-2 is involved in the regulation of a wide range of biological processes, including development, reproduction, memory, and stress responses.

DAF-2 was originally discovered for its role in controlling the dauer stage – an alternative stage of development in which a larva goes into a type of stasis to help it survive harsh conditions (Riddle et al., 1981). A lack of DAF-2 causes C. elegans to enter dauer, as does a lack of a number of other kinases (Paradis and Ruvkun, 1998). An ongoing mystery is why C. elegans has just a single gene for an insulin receptor despite having 40 different insulin-like peptides (Pierce et al., 2001). Some of these peptides are agonists (that is, they activate the receptor) and others are antagonists (they inhibit the receptor).

Given three decades of extensive research into the insulin signaling pathway in C. elegans, it would be shocking to find new functions for DAF-2 at this point. However, in a new paper in eLife, Matthew Gill of the Scripps Research Institute and colleagues – including Bryan Martinez and Pedro Reis Rodrigues as joint first authors – report evidence for such a shock: the gene for DAF-2 can also express another, truncated isoform of this protein as a result of alternative splicing (Martinez et al., 2020). The truncated version, which is called DAF-2B, can still form dimers but, unlike the full-length version, it is not expected to be able to span the membrane: this suggests that the truncated form could be secreted.

Truncated insulin receptors that have extracellular ligand-binding domains, but lack intracellular signaling domains, have been reported in both Drosophila and mammals, and are known to sequester insulin peptides. However, in these cases the full-length receptors and the truncated receptors are expressed from separate genes. Martinez et al. found that although DAF-2B was expressed in neuronal cells, it accumulated in cells called coelomocytes (macrophage-like cells that attack invading organisms such as bacteria and viruses). These results suggest that DAF-2B can indeed be secreted, rather than being retained in the neurons in which it is expressed and spliced.

But what does this shortened form of DAF-2 do? The best-characterized functions of the insulin signaling pathway are dauer formation and lifespan regulation, so Martinez et al. used these phenotypes to study DAF-2B. They found that overexpressing DAF-2B increased dauer formation, slowed dauer exit, and increased lifespan, whereas a lack of DAF-2B had the opposite effect. Basically, the data suggest that the function of DAF-2B is essentially the opposite of the function of DAF-2.

Martinez et al. also explored the interactions between DAF-2B and insulin-like peptides that were either agonists or antagonists. Overexpression of two peptides that are agonists (DAF-28 and INS-6) reduced the dauer-promoting effects of DAF-2B. Conversely, the overexpression of a peptide that is an antagonist (INS-18) would be expected to promote dauer, but this effect was blunted when DAF-2B was also overexpressed. Additionally, the researchers found that a point mutation in the proposed insulin-binding domain resulted in a form of DAF-2B that exhibited reduced dauer formation. Together, these results suggest that DAF-2B binds and may sequester insulin-like peptides, and/or form dimers with DAF-2.

Of course, mysteries remain. Given that worms have dozens of insulin-like peptides (Pierce et al., 2001), which of these bind to DAF-2B, and under what circumstances? And if DAF-2B is secreted, why does it matter where it is expressed, unless there are highly localized interactions? Finally, the mechanism by which DAF-2B acts and its dimerization state is not entirely understood.

The discovery of the truncated version of DAF-2, and the fact that it essentially works in opposition to the full-length version, raises new questions and will change how we think about DAF-2's role in insulin signaling regulation of aging and longevity.

References

Article and author information

Author details

  1. Coleen T Murphy

    Coleen T Murphy is in the Department of Molecular Biology and LSI Genomics, Princeton University, Princeton, United States

    For correspondence
    ctmurphy@princeton.edu
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-8257-984X

Publication history

  1. Version of Record published: February 25, 2020 (version 1)

Copyright

© 2020, Murphy

This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 3,007
    Page views
  • 165
    Downloads
  • 1
    Citations

Article citation count generated by polling the highest count across the following sources: Crossref, PubMed Central, Scopus.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Coleen T Murphy
(2020)
Aging and Longevity: Short and sweet
eLife 9:e55220.
https://doi.org/10.7554/eLife.55220

Further reading

    1. Developmental Biology
    Nicolas G Brukman, Clari Valansi, Benjamin Podbilewicz
    Research Article Updated

    The fusion of mammalian gametes requires the interaction between IZUMO1 on the sperm and JUNO on the oocyte. We have recently shown that ectopic expression of mouse IZUMO1 induces cell-cell fusion and that sperm can fuse to fibroblasts expressing JUNO. Here, we found that the incubation of mouse sperm with hamster fibroblasts or human epithelial cells in culture induces the fusion between these somatic cells and the formation of syncytia, a pattern previously observed with some animal viruses. This sperm-induced cell-cell fusion requires a species-matching JUNO on both fusing cells, can be blocked by an antibody against IZUMO1, and does not rely on the synthesis of new proteins. The fusion is dependent on the sperm’s fusogenic capacity, making this a reliable, fast, and simple method for predicting sperm function during the diagnosis of male infertility.

    1. Biochemistry and Chemical Biology
    2. Developmental Biology
    Sima Stroganov, Talia Harris ... Michal Neeman
    Research Article Updated

    Background:

    Fetal growth restriction (FGR) is a pregnancy complication in which a newborn fails to achieve its growth potential, increasing the risk of perinatal morbidity and mortality. Chronic maternal gestational hypoxia, as well as placental insufficiency are associated with increased FGR incidence; however, the molecular mechanisms underlying FGR remain unknown.

    Methods:

    Pregnant mice were subjected to acute or chronic hypoxia (12.5% O2) resulting in reduced fetal weight. Placenta oxygen transport was assessed by blood oxygenation level dependent (BOLD) contrast magnetic resonance imaging (MRI). The placentae were analyzed via immunohistochemistry and in situ hybridization. Human placentae were selected from FGR and matched controls and analyzed by immunohistochemistry (IHC). Maternal and cord sera were analyzed by mass spectrometry.

    Results:

    We show that murine acute and chronic gestational hypoxia recapitulates FGR phenotype and affects placental structure and morphology. Gestational hypoxia decreased labyrinth area, increased the incidence of red blood cells (RBCs) in the labyrinth while expanding the placental spiral arteries (SpA) diameter. Hypoxic placentae exhibited higher hemoglobin-oxygen affinity compared to the control. Placental abundance of Bisphosphoglycerate mutase (BPGM) was upregulated in the syncytiotrophoblast and spiral artery trophoblast cells (SpA TGCs) in the murine gestational hypoxia groups compared to the control. Hif1α levels were higher in the acute hypoxia group compared to the control. In contrast, human FGR placentae exhibited reduced BPGM levels in the syncytiotrophoblast layer compared to placentae from healthy uncomplicated pregnancies. Levels of 2,3 BPG, the product of BPGM, were lower in cord serum of human FGR placentae compared to control. Polar expression of BPGM was found in both human and mouse placentae syncytiotrophoblast, with higher expression facing the maternal circulation. Moreover, in the murine SpA TGCs expression of BPGM was concentrated exclusively in the apical cell side, in direct proximity to the maternal circulation.

    Conclusions:

    This study suggests a possible involvement of placental BPGM in maternal-fetal oxygen transfer, and in the pathophysiology of FGR.

    Funding:

    This work was supported by the Weizmann Krenter Foundation and the Weizmann – Ichilov (Tel Aviv Sourasky Medical Center) Collaborative Grant in Biomedical Research, by the Minerva Foundation, by the ISF KillCorona grant 3777/19.